Christina Arce

847 total citations · 1 hit paper
18 papers, 580 citations indexed

About

Christina Arce is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Christina Arce has authored 18 papers receiving a total of 580 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Christina Arce's work include Advanced Breast Cancer Therapies (15 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (6 papers). Christina Arce is often cited by papers focused on Advanced Breast Cancer Therapies (15 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (6 papers). Christina Arce collaborates with scholars based in United States, France and Spain. Christina Arce's co-authors include Laurence Hirsch, Michael A. Gibney, Dejan Juric, Florence Lerebours, Stephen Chia, Hope S. Rugo, Pamela Drullinsky, Aleix Prat, Nicholas C. Turner and Eva Ciruelos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Christina Arce

18 papers receiving 558 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 223 citations Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Christina Arce

Since Specialization

Citations

This map shows the geographic impact of Christina Arce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Arce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Arce more than expected).

Fields of papers citing papers by Christina Arce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Arce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Arce. The network helps show where Christina Arce may publish in the future.

Co-authorship network of co-authors of Christina Arce

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Arce. A scholar is included among the top collaborators of Christina Arce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Arce. Christina Arce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study 2024 ·The Lancet Oncology ·Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, (unknown), Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia	10
2	Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study 2022 ·Cancer Research ·Dejan Juric, Nicholas Turner, Aleix Prat, Stephen Chia, Eva Ciruelos, Manuel Ruíz‐Borrego, Pamela Drullinsky, Florence Lerebours, Thomas Bachelot, O. Alejandro Balbin, (unknown), (unknown), Christina Arce, (unknown), Hope S. Rugo	3
3	Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses 2022 ·Cancer Research ·Hope S. Rugo, Patrick Neven, (unknown), Yeon Hee Park, Michelino De Laurentiis, Florence Lerebours, Eva Ciruelos, Nicholas C. Turner, Dejan Juric, (unknown), Christina Arce, (unknown), (unknown), (unknown), Stephen Chia	6
4	Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial 2022 ·Cancer Research ·Nicholas C. Turner, Hope S. Rugo, Eva Ciruelos, Manuel Ruíz‐Borrego, Pamela Drullinsky, Florence Lerebours, Aleix Prat, Thomas Bachelot, Stephen Chia, (unknown), (unknown), (unknown), Christina Arce, (unknown), Dejan Juric	2
5	175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study 2022 ·Annals of Oncology ·Filipa Cardoso, Dejan Juric, F. Lerebours, Ian E. Krop, Manuel Ruíz Borrego, Patrick Neven, Y.H. Park, Denise A. Yardley, Komal Jhaveri, Christina Arce, (unknown), (unknown), H. S. Rugo	1
6	Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve 2022 ·Cancer Research ·Stephen Chia, Eva Ciruelos, Hope S. Rugo, Florence Lerebours, Manuel Ruíz‐Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Nicholas Turner, (unknown), Christina Arce, (unknown), Dejan Juric	1
7	Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. 2022 ·Journal of Clinical Oncology ·Dejan Juric, Hope S. Rugo, Stephen Chia, Florence Lerebours, Manuel Ruíz‐Borrego, Pamela Drullinsky, Eva Ciruelos, Patrick Neven, Yeon Hee Park, Christina Arce, (unknown), (unknown), (unknown), (unknown), Nicholas C. Turner	3
8	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A 2022 ·Cancer Research ·Eva Ciruelos, Florence Lerebours, Hope S. Rugo, Manuel Ruíz‐Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Patrick Neven, Yeon Hee Park, Nicholas Turner, Dejan Juric, (unknown), Christina Arce, (unknown), Stephen Chia	1
9	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study breakdown → 2021 ·The Lancet Oncology ·Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, (unknown), Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia	223
10	Abstract PD2-07: Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results 2021 ·Cancer Research ·Hope S. Rugo, Florence Lerebours, Dejan Juric, Nicholas C. Turner, Stephen Chia, Pamela Drullinsky, Aleix Prat, Rafael Villanueva-Vázquez, (unknown), Christina Arce, (unknown), Eva Ciruelos	9
11	Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve. 2021 ·Journal of Clinical Oncology ·Stephen Chia, Manuel Ruíz‐Borrego, Pamela Drullinsky, Dejan Juric, Thomas Bachelot, Hope S. Rugo, Eva Ciruelos, Florence Lerebours, Aleix Prat, (unknown), Christina Arce, (unknown), Nicholas C. Turner	1
12	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. 2020 ·Journal of Clinical Oncology ·Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, (unknown), Stephen Chia	35
13	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer 2018 ·JAMA Oncology ·Melanie Royce, Thomas Bachelot, Cristian Villanueva, Mustafa Özgüroğlu, Sérgio Jobim Azevedo, Felipe Melo Cruz, Marc Debled, Roberto Hegg, Tatsuya Toyama, Carla I. Falkson, Joon Jeong, Vichien Srimuninnimit, William J. Gradishar, Christina Arce, Antonia Ridolfi, (unknown), Fátima Cardoso	50
14	Everolimus (EVE) + letrozole (LET) in Asian patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Results of a subgroup analysis from the BOLERO-4 study 2017 ·Annals of Oncology ·Tatsuya Toyama, Joon Jeong, Vichien Srimuninnimit, Virote Sriuranpong, Woo Chul Noh, Koichiro Tsugawa, Masato Takahashi, Hirotaka Iwase, Christina Arce, Antonia Ridolfi, (unknown), Melanie Royce, Fátima Cardoso	2
15	Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study. 2017 ·Journal of Clinical Oncology ·Fátima Cardoso, Cristian Villanueva, Melanie Royce, Felipe Melo Cruz, Marc Debled, Roberto Hegg, Tatsuya Toyama, Carla I. Falkson, Joon Jeong, Vichien Srimuninnimit, Mustafa Özgüroğlu, William J. Gradishar, Sérgio Jobim Azevedo, Christina Arce, Antonia Ridolfi, (unknown), Thomas Bachelot	7
16	Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure 2011 ·Current Medical Research and Opinion ·(unknown), Ingrid Eshun‐Wilson, Christina Arce, Christopher R. Ellis, Valentin Parvu, David Hassman, Kenneth Kassler-Taub	7
17	HIF-1a and target genes as metabolic biomarkers in Mexican women with breast cancer. 2011 ·Journal of Clinical Oncology ·Sara Rodríguez‐Enríquez, (unknown), Cynthia Villarreal‐Garza, Rosina Moreno, (unknown), (unknown), Christina Arce, (unknown), (unknown)	1
18	Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations 2010 ·Current Medical Research and Opinion ·Michael A. Gibney, Christina Arce, (unknown), Laurence Hirsch	218

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact